Biogen's potentially game-changing Alzheimer's drug still faces an uphill battle with the FDA
December 07, 2019 at 15:35 PM EST
"It's a complete coin flip that will now be in the hands of the FDA," says Jared Holz, a health-care strategist at Jefferies.
